Overview

Masitinib is developed in several human indications, in oncology, inflammatory diseases, and central nervous system diseases. Masitinib has been evaluated in over 2000 human patients to date. 

Masitinib also generated positive phase 2 results in oncology, inflammatory diseases, as well as CNS diseases. Several phases 3 are on-going in those indications.


Area Indication Study Status
Oncology / Hematology GIST in first-line treatment Phase 3 On-going
GIST in second-line treatment Phase 3 confirmatory On-going
Metastatic melanoma with JM mutation of c-KIT Phase 3 On-going
Relapsed metastatic colorectal cancer Phase 3 On-going
Relapsed multiple myeloma Phase 3 On-going
Metastatic Castrate Resistant Prostate Cancer in first line Phase 3 On-going
Pancreatic cancer Phase 3 confirmatory Authorized
Relapsed metastatic non-small cell lung cancer Phase 2 On-going
Relapsed metastatic triple negative breast cancer Phase 2 On-going
Relapsed metastatic non triple negative breast cancer Phase 2 On-going
Relapsed metastatic melanoma Phase 2 On-going
Relapsed metastatic liver cancer Phase 2 On-going
Relapsed metastatic gastric cancer Phase 2 On-going
Relapsed metastatic head and neck cancer Phase 2 On-going
Relapsed glioblastoma multiforme Phase 2 On-going
Relapsed peripheral T-cell lymphoma Phase 2 On-going
Non Oncology Indolent Systemic Mastocytosis Phase 3 On-going
Non controlled severe asthma Phase 3 On-going
Refractory rheumatoid arthritis Phase 3 On-going
Alzheimer's disease Phase 3 On-going
Progressive forms of multiple sclerosis Phase 3 On-going
Amyothrophic Lateral Sclerosis Phase 3 On-going